{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T08:11:02Z","timestamp":1769155862799,"version":"3.49.0"},"reference-count":7,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2021,4,15]],"date-time":"2021-04-15T00:00:00Z","timestamp":1618444800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,4,15]],"date-time":"2021-04-15T00:00:00Z","timestamp":1618444800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1007\/s00277-021-04524-w","type":"journal-article","created":{"date-parts":[[2021,4,15]],"date-time":"2021-04-15T22:02:17Z","timestamp":1618524137000},"page":"441-442","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Ixazomib as treatment for pyoderma gangrenosum associated with IgA smoldering multiple myeloma"],"prefix":"10.1007","volume":"101","author":[{"given":"David Alvarez","family":"Cespedes","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephanie M.","family":"Gallitano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5482-7543","authenticated-orcid":false,"given":"Divaya","family":"Bhutani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,4,15]]},"reference":[{"issue":"4","key":"4524_CR1","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1016\/j.jaad.2015.06.021","volume":"73","author":"SF Braswell","year":"2015","unstructured":"Braswell SF, Kostopoulos TC, Ortega-Loayza AG (2015) Pathophysiology of pyoderma gangrenosum (PG): an updated review. J Am Acad Dermatol 73(4):691\u2013698","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"4524_CR2","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1001\/jamadermatol.2017.5980","volume":"154","author":"E Maverakis","year":"2018","unstructured":"Maverakis E, Ma C, Shinkai K, Fiorentino D, Callen JP, Wollina U, Marzano AV, Wallach D, Kim K, Schadt C, Ormerod A, Fung MA, Steel A, Patel F, Qin R, Craig F, Williams HC, Powell F, Merleev A, Cheng MY (2018) Diagnostic criteria of ulcerative pyoderma gangrenosum: a Delphi consensus of international experts. JAMA Dermatol 154(4):461\u2013466","journal-title":"JAMA Dermatol"},{"issue":"17","key":"4524_CR3","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1080\/14656566.2018.1528229","volume":"19","author":"PG Richardson","year":"2018","unstructured":"Richardson PG, Zweegman S, O\u2019Donnell EK, Laubach JP, Raje N, Voorhees P, Ferrari RH, Skacel T, Kumar SK, Lonial S (2018) Ixazomib for the treatment of multiple myeloma. Expert Opin Pharmacother 19(17):1949\u20131968","journal-title":"Expert Opin Pharmacother"},{"issue":"6","key":"4524_CR4","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1016\/j.jaad.2019.09.032","volume":"82","author":"CM Montagnon","year":"2020","unstructured":"Montagnon CM, Fracica EA, Patel AA, Camilleri MJ, Murad MH, Dingli D, Wetter DA, Tolkachjov SN (2020) Pyoderma gangrenosum in hematologic malignancies: a systematic review. J Am Acad Dermatol 82(6):1346\u20131359","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"4524_CR5","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1111\/iwj.12746","volume":"14","author":"V Velasco-Tamariz","year":"2017","unstructured":"Velasco-Tamariz V, Carre\u00f1o-Tarragona G, Tous-Romero F (2017) Gil-de la Cruz E, Mart\u00edn-Clavero E, Rivera-D\u00edaz R. Dramatic resolution of disseminated pyoderma gangrenosum associated with monoclonal gammopathy after therapy with bortezomib and dexamethasone. Int Wound J 14(6):1382\u20131384","journal-title":"Int Wound J"},{"issue":"4","key":"4524_CR6","doi-asserted-by":"publisher","first-page":"iwj.13135","DOI":"10.1111\/iwj.13135","volume":"16","author":"E Bostan","year":"2019","unstructured":"Bostan E, G\u00fcnayd\u0131n SD, Karaduman A et al (2019) Excellent response to bortezomib in a patient with widespread ulcerative pyoderma gangrenosum accompanied by pulmonary involvement and IgA monoclonal gammopathy. Int Wound J 16(4):iwj.13135","journal-title":"Int Wound J"},{"issue":"6","key":"4524_CR7","doi-asserted-by":"publisher","first-page":"711","DOI":"10.2169\/internalmedicine.55.5853","volume":"55","author":"Y Kikuchi","year":"2016","unstructured":"Kikuchi Y, Yoshimi M, Takahashi T (2016) Pyoderma gangrenosum in a patient with multiple myeloma. Intern Med 55(6):711","journal-title":"Intern Med"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-021-04524-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-021-04524-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-021-04524-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,8]],"date-time":"2022-01-08T09:02:57Z","timestamp":1641632577000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-021-04524-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,15]]},"references-count":7,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["4524"],"URL":"https:\/\/doi.org\/10.1007\/s00277-021-04524-w","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,15]]},"assertion":[{"value":"23 March 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 April 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Informed consent was obtained from participant included in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Divaya Bhutani has received research funding from Sanofi pharmaceuticals and also serves on the advisory board for Sanofi Pharmaceuticals. David Alvarez Cespedes and Stephanie Gallitano declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}